sanofi

28th September 2026

To,

The Secretary	The Secretary
BSE Limited	The National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers	Exchange Plaza, C-1, Block G,
Dalal Street	Bandra-Kurla Complex,
Mumbai 400 001	Bandra (E), Mumbai 400 051
Scrip Code: 500674	Symbol: SANOFI

Dear Sir / Madam,

Sub.: Disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SAST Regulations") in respect of inter se transfer of shares exempted under Regulation 10(1)(a)(iii) of the SAST Regulations

With reference to the abovementioned subject, Sanofi Healthcare India Private Limited, an entity part of the promoter group of Sanofi India Limited ("Target Company") has acquired 3,500,000 equity shares representing 15.20% of the equity share capital of the Target Company from Hoechst GmbH, a promoter of the Target Company, on 24th September 2026.

This acquisition is an inter-se transfer among members of the promoter and promoter group of the Target Company through a block deal mechanism on the Stock Exchange and falls within the exemption provided under Regulation 10(1)(a)(iii) of the SAST Regulations. The prior intimation under Regulation 10(5) of the SAST Regulations was submitted on 17th September 2026. The aggregate holding of promoter and promoter group before and after the above inter-se transfer remains unchanged.

In this regard, please find enclosed herewith the disclosure pursuant to the provision of Regulation 10(6) of the SAST Regulations in the specified format as required to be given for the said acquisition of the equity shares of the Target Company.

This is for your information and records.

Thanking you.

Yours faithfully,
For **Sanofi Healthcare India Private Limited**

Neha Pukhraj Pokhrana
Digitally signed by Neha Pukhraj Pokhrana
Date: 2026.09.28 14:36:59 +05'30'

Neha Pokhrana
Company Secretary
Membership No.: A40082

Encl.: As above

Cc:
Mr. Haresh Vala
Company Secretary and Compliance officer
Sanofi India Limited
Address: Sanofi House, CTS No. 117-B,
L&T Business Park, Saki Vihar Road,
Powai, Mumbai 400 072

sanofi

DISCLOSURES UNDER REGULATION 10(6) – REPORT TO STOCK EXCHANGES IN RESPECT OF ANY ACQUISITION MADE IN RELIANCE UPON EXEMPTION PROVIDED FOR IN REGULATION 10 OF SECURITIES AND EXCHANGE BOARD OF INDIA (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011

1.	Name of the Target Company (TC)	Sanofi India Limited ("**Target Company**")
2.	Name of the acquirer(s)	Sanofi Healthcare India Private Limited ("**Acquirer**")
3.	Name of the stock exchange where shares of the TC are listed	BSE Limited The National Stock Exchange of India Limited
4.	Details of the transaction including rationale, if any, for the transfer / acquisition of shares.	The Acquirer has acquired 3,500,000 equity shares carrying 15.20% of the equity share capital of the Target Company from Hoechst GmbH, a promoter of the Target Company, on 24th September 2026. The transaction is being undertaken through the block deal mechanism on the Stock Exchange as an inter-se transfer of shareholding among members of the promoter and promoter group of the Target Company.
5.	Relevant regulation under which the acquirer is exempted from making open offer.	The Acquirer is exempted from the requirement to make an open offer in terms of Regulation 10(1)(a)(iii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("**SAST Regulations**"). Sub-clause (iii) of the SAST Regulations 10(1)(a) states: *"a company, its subsidiaries, its holding company, other subsidiaries of such holding company, persons holding not less than fifty per cent of the equity shares of such company, other companies in which such persons hold not less than fifty per cent of the equity shares, and their subsidiaries subject to control over such qualifying persons being exclusively held by the same persons;* *Explanation: For the purpose of this sub-clause, the company shall include a body corporate, whether Indian or foreign."*
6.	Whether disclosure of proposed acquisition was required to be made under regulation 10 (5) and if so, - whether disclosure was made and whether it was made within the timeline specified under the regulations. - date of filing with the stock exchange.	- Yes, the disclosure under Regulation 10(5) of the SAST Regulations was required to be made for the acquisition and was filed within the timeline specified under the SAST Regulations. - The disclosure was filed with the Stock Exchanges on 17th September 2026.

sanofi

7.	Details of acquisition		Disclosures required to be made under Regulation 10(5)	Whether the disclosures under Regulation 10(5) are actually made
	a.	Name of the transferor / seller	Hoechst GmbH	Yes
	b.	Date of acquisition	24th September 2026	Yes
	c.	Number of shares / voting rights in respect of the acquisitions from each person mentioned in 7(a) above	3,500,000	Yes
	d.	Total shares ~~proposed to be acquired /~~ actually acquired as a % of diluted share capital of TC	15.20%	Yes
	e.	Price at which shares are ~~proposed to be acquired /~~ actually acquired	Rs. 3,052 per share	Yes

8.	Shareholding details		Pre-Transaction		Post-Transaction	
			No. of shares held	% w.r.t total share capital of TC	No. of shares held	% w.r.t total share capital of TC
	a	Each Acquirer / Transferee and PAC (other than sellers) (*)				
		Sanofi Healthcare India Private Limited (Acquirer)	Nil	Nil	3,500,000	15.20
		PAC:				
		1. SANOFI	4,865	0.02	4,865	0.02
		2. CKW PHARMA EXTRAKT BETEILIGUNGS UND VERWALTUNGS Gm	Nil	Nil	Nil	Nil
		3. CKW PHARMA EXTRAKT GMBH & Co.KG	Nil	Nil	Nil	Nil
		4. Future Capital AG Hessen Life Sciences Chemie	Nil	Nil	Nil	Nil
		5. Sanofi Aventis de Colombia S.A.	Nil	Nil	Nil	Nil
		6. Sanofi Aventis Deutschland GmbH	Nil	Nil	Nil	Nil
		7. Starlink Logistics Inc. (SLLI)	Nil	Nil	Nil	Nil
		8. Aventis Agriculture	Nil	Nil	Nil	Nil
		9. CARRAIG INSURANCE DAC	Nil	Nil	Nil	Nil
		10. Sanofi Cathay (Shanghai) Private Equity Investment Fund Partnership (L.P.)	Nil	Nil	Nil	Nil
		11. Innobio 2	Nil	Nil	Nil	Nil
		12. Le Rock Re	Nil	Nil	Nil	Nil
		13. Limited Liability Company Sanofi Aventis Ukraine	Nil	Nil	Nil	Nil

sanofi

		14. Sanofi Aventis del Peru S.A	Nil	Nil	Nil	Nil
		15. Sanofi Aventis Groupe	Nil	Nil	Nil	Nil
		16. Sanofi Aventis Korea Co., Ltd.	Nil	Nil	Nil	Nil
		17. Sanofi Aventis Participations	Nil	Nil	Nil	Nil
		18. Sanofi Aventis Recherche & Développement	Nil	Nil	Nil	Nil
		19. Sanofi B.V.	Nil	Nil	Nil	Nil
		20. Cathay Growth (Quanzhou) Equity Investment Fund L.P	Nil	Nil	Nil	Nil
		21. Sanofi European Treasury Center	Nil	Nil	Nil	Nil
		22. Sanofi Foreign Participations B.V.	Nil	Nil	Nil	Nil
		23. SANOFI GESTION SA	Nil	Nil	Nil	Nil
		24. SANOFI PASTEUR MERIEUX	Nil	Nil	Nil	Nil
		25. Sanofi R&D Vaccins	Nil	Nil	Nil	Nil
		26. Sanofi sp. z.o.o.	Nil	Nil	Nil	Nil
		27. Sanofi (China) Investment Co. Ltd.	Nil	Nil	Nil	Nil
		TOTAL	**4,865**	**0.02**	**3,504,865**	**15.22**
	b.	Each Seller/ Transferor				
		Hoechst GmbH	13,904,722	60.38	10,404,722	45.18

Note: (*) Shareholding of each entity shall be shown separately and then collectively in a group.

For Sanofi Healthcare India Private Limited

Neha Pukhraj Pokhrana
Digitally signed by Neha Pukhraj Pokhrana
Date: 2026.09.28 14:38:08 +05'30'

Neha Pokhrana
Company Secretary
Membership No.: A40082

Date: 28th September 2026
Place: Mumbai